Sanofi’s bad, aw­ful, ter­ri­ble de­vel­op­ment week ends with PhI­II C. diff fail­ure

Fri­day marks the end of Sanofi’s bad, aw­ful, ter­ri­ble week of vac­cine de­vel­op­ment news.

The phar­ma gi­ant $SNY says it will ter­mi­nate its late-stage pro­gram for a Clostrid­i­um dif­fi­cile vac­cine af­ter in­ves­ti­ga­tors de­ter­mined they were on a straight path to fail­ure.

The set­back fol­lows fast on the news that Sanofi has con­ced­ed that its one-time ‘block­buster’ dengue vac­cine was dan­ger­ous when giv­en to any­one who had not yet ex­pe­ri­enced an in­fec­tion. Sanofi wrote off $120 mil­lion on a pro­gram it once reck­oned was worth more than $1 bil­lion a year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER